mestranol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
estrogens 1714 72-33-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mestranol
  • ethynylestradiol methyl ether
  • inostral
  • menophase
  • norquen
  • 3-Methoxyethynylestradiol
The 3-methyl ether of ETHINYL ESTRADIOL. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL CONTRACEPTIVES.
  • Molecular weight: 310.44
  • Formula: C21H26O2
  • CLOGP: 4.27
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 29.46
  • ALOGS: -4.92
  • ROTB: 1
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.417 Moderate 0.78
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.074 Moderate 0.78
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 13.804 10^-6 cm/s Moderate 0.78
dh-clint Dog hepatocyte intrinsic clearance 38.282 uL/min/10^6 cells Moderate 0.78
dppb Dog plasma protein binding (% unbound) 0.410 % Moderate 0.78
fcs-ppb Fetal calf serum protein binding (% unbound) 0.500 % Moderate 0.78
herg hERG pIC50 5.043 pIC50 Moderate 0.78
hh-clint Human hepatocyte intrinsic clearance 34.041 uL/min/10^6 cells Moderate 0.78
hlm-clint Human liver microsomal intrinsic clearance 26.546 uL/min/mg protein Moderate 0.78
hppb Human plasma protein binding (% unbound) 0.500 % Moderate 0.78
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PRKDC,TEK,TGFBR1,ZAP70 25
kinase-selectivity-class EIF2AK3,GRK2 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.203 Moderate 0.78
mh-clint Mouse hepatocyte intrinsic clearance 94.406 Moderate 0.78
mppb Mouse plasma protein binding (% unbound) 0.600 Moderate 0.78
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.470 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.78
pppb Pig plasma protein binding (% unbound) 0.460 % Moderate 0.78
rh-clint Rat hepatocyte intrinsic clearance 69.663 uL/min/10^6 cells Moderate 0.78
rh-fuinc Rat hepatocyte fraction unbound in incubation 4.840 % Moderate 0.78
rppb Rat plasma protein binding (% unbound) 0.500 % Moderate 0.78
solubility-dd Solubility at pH 7.4 in DMSO 0.925 uM Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
March 9, 1961 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000000100 Estrogen Receptor Agonists
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D003271 Contraceptive Agents, Female
MeSH PA D003278 Contraceptives, Oral, Hormonal
MeSH PA D004967 Estrogens
MeSH PA D006728 Hormones
MeSH PA D012102 Reproductive Control Agents
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:76988 xenoestrogen
FDA EPC N0000175825 Estrogen

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Contraception indication 13197004
Female hypogonadism syndrome indication 16041008
Endometriosis indication 129103003
Menorrhagia indication 386692008
Heart valve disorder contraindication 368009 DOID:4079
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Hyperlipidemia contraindication 55822004 DOID:1168
Benign mammary dysplasia contraindication 57993004
Obstructive hyperbilirubinemia contraindication 59848001
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Deep venous thrombosis contraindication 128053003
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Endometrial carcinoma contraindication 254878006 DOID:2871
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Malignant tumor of cervix contraindication 363354003 DOID:4362
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication
Major Surgery with Prolonged Post-Operative Immobilization contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor AGONIST Ki 8.28 DRUG MATRIX CHEMBL
Cannabinoid receptor 1 GPCR Ki 4.65 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 7.66 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.86 DRUG MATRIX
Androgen receptor Transcription factor Ki 5.15 DRUG MATRIX
Progesterone receptor Transcription factor Ki 4.96 DRUG MATRIX

External reference:

IDSource
4018119 VUID
N0000146457 NUI
D00575 KEGG_DRUG
4018119 VANDF
C0025506 UMLSCUI
CHEBI:6784 CHEBI
CHEMBL1201151 ChEMBL_ID
DB01357 DRUGBANK_ID
D008656 MESH_DESCRIPTOR_UI
6291 PUBCHEM_CID
7087 IUPHAR_LIGAND_ID
1139 INN_ID
B2V233XGE7 UNII
6782 RXNORM
5059 MMSL
d03038 MMSL
001273 NDDF
395785001 SNOMEDCT_US
77885004 SNOMEDCT_US
B2V233XGE7 INXIGHT DRUGS

Pharmaceutical products:

None